Effects of the CYP2C19 genotype and cigarette smoking on the single oral dose pharmacokinetics and pharmacodynamics of estazolam

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 3, 2003, Pages 535-538

  Aoshima, Toshiaki ^a   Fukasawa, Takashi ^a   Otsuji, Yohei ^a   Okuyama, Naoyuki ^a   Gerstenberg, Gisa ^a   Miura, Masatomo ^b   Ohkubo, Tadashi ^b   Sugawara, Kazunobu ^b   Otani, Koichi ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

CYP2C19; Estazolam; Pharmacodynamics; Pharmacokinetics; Smoking

Indexed keywords

CYTOCHROME P450 2C19; ESTAZOLAM;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME ANALYSIS; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PSYCHOMOTOR ACTIVITY;

EID: 0037402548     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00357-3     Document Type: Article

References (21)

1. Andersson T., Cederberg C., Edvardsson G., Heggelund A., Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin. Pharmacol. Ther. 47:1990;79-85.
2. Bertilsson L., Henthorn T.K., Sanz E., Tybring G., Sawe J., Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin. Pharmacol. Ther. 45:1989;348-355.
3. de Morais S.M., Goldstein J.A., Xie H.G., Huang S.L., Lu Y.Q., Xia H., Xiao Z.S., Ile N., Zhou H.H. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin. Pharmacol. Ther. 58:1995;404-411.
4. Goldstein J.A., Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol. 272:1996;210-218.
5. Goldstein J.A., de Morais S.M.F. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 4:1994;285-299.
6. Greenblatt D.J., Shader R.I., Harmatz J.S., Franke K., Koch-Weser J. Absorption rate, blood concentrations, and early response to oral chlordiazepoxide. Am. J. Psychiatry. 134:1977;559-562.
7. Hoddes E., Zarcone V., Smythe H., Phillips R., Dement W.C. Quantification of sleepiness: a new approach. Psychophysiology. 10:1973;413-436.
8. Ishida M., Otani K., Kaneko S., Okubo T., Osanai T., Yasui N., Mihara K., Higuchi H., Sugawara K. Effects of various factors on steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int. Clin. Psychopharmacol. 10:1995;143-146.
9. Kilicarslan T., Haining R.L., Rettie A.E., Busto U., Tyndale R.F., Sellers E.M. Flunitrazepan metabolism by cytochrome P450s 2C19 and 3A4. Drug Metab. Dispos. 29:2001;460-465.
10. 14C-estazolam in dogs and humans. Xenobiotica. 16:1986;11-20.
11. Miller L.G. Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clin. Pharm. 9:1990;125-135.
12. Miura M., Ohkubo T., Sugawara K., Okuyama N., Otani K. Determination of estazolam in plasma by high-performance liquid chromatography with solid-phase extraction. Anal. Sci. 18:2002;525-528.
13. Nakajima R., Saji Y., Kazato Y., Mikoda R., Tanayama S., Nagawa Y. Dissociative change in antiaggressive and muscle relaxant actions of S-triazolobenzodiazepine (D-40TA) by repeated administration and phenobarbital pretreatment, and its relation to metabolism. J. Takeda Res. Lab. 32:1973;264-274.
14. Otani K., Kondo T., Kaneko S., Hirano T., Mihara K., Fukushima Y. Steady-state serum kinetics of zotepine. Hum. Psychopharmacol. 7:1992;331-336.
15. Otani K., Yasui N., Kaneko S., Ohkubo T., Osanai T., Sugawara K., Hayashi K., Chiba K., Ishizaki T. Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam. Neuropsychopharmacology. 16:1997;8-14.
16. Otsuji Y., Okuyama N., Aoshima T., Fukasawa T., Kato K., Gerstenberg G., Miura M., Ohkubo T., Sugawara K., Otani K. No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam. Ther. Drug Monit. 24:2002;375-378.
17. Pierce M.W., Shu V.S. Efficacy of estazolam: the United States clinical experience. Am. J. Med. 88(Suppl. 3A):1990;S6-S11.
18. Pierce M.W., Shu V.S., Groves L.J. Safety of estazolam: the United States clinical experience. Am. J. Med. 88(Suppl. 3A):1990;S12-S17.
19. Qin X.P., Xie H.G., Wang W., He N., Huang S.L., Xu Z.H., Ou-Yang D.S., Wang Y.J., Zhou H.H. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. Clin. Pharmacol. Ther. 66:1999;642-646.
20. Schein J.R. Cigarette smoking and clinically significant drug interactions. Ann. Pharmacother. 29:1995;1139-1148.
21. Yasui N., Otani K., Ohkubo T., Osanai T., Sugawara K., Chiba K., Ishizaki T., Kaneko S. Single-dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P450 2C19(CYP2C19) activity. Ther. Drug Monit. 19:1997;371-374.